SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-007264
Filing Date
2023-03-10
Accepted
2023-03-10 16:03:05
Documents
12
Period of Report
2023-03-10
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K tals-20230310.htm   iXBRL 8-K 52443
  Complete submission text file 0000950170-23-007264.txt   173353

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tals-20230310_pre.xml EX-101.PRE 10281
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tals-20230310.xsd EX-101.SCH 2460
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tals-20230310_lab.xml EX-101.LAB 14018
6 EXTRACTED XBRL INSTANCE DOCUMENT tals-20230310_htm.xml XML 4931
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 23723561
SIC: 2836 Biological Products, (No Diagnostic Substances)